The frequency of undesirable effects is defined as follows:
• Very Common (≥ 1/10)
• Common (≥1/100, <1/10)
• Uncommon (≥1/1,000, <1/100)
• Rare (≥1/10,000, <1/1,000)
• Very Rare (<1/10,000)
• Not known (cannot be estimated from the available data).
The following adverse reactions have been identified during clinical studies of 0.5% w/v and 1.0% w/v Celluvisc Eye drops, solution, unit dose.
Eye disorders:
Common: Eye irritation (including burning and discomfort), eye pain, eye pruritus, visual disturbance.
Postmarketing Experience
The following additional adverse reactions have been identified during postmarketing use of Celluvisc 1.0% in clinical practice.
Immune System Disorders
Uncommon: Hypersensitivity including eye allergy with symptoms of eye swelling or eyelid edema.
Eye Disorders
Uncommon: Lacrimation increased, vision blurred, eye discharge, eyelid margin crusting and/or medication residue, foreign body sensation in eye, ocular hyperemia, visual impairment.
Injury, Poisons and Procedural Complications
Uncommon: Superficial injury of eye (
from the vial tip touching the eye during administration) and/or corneal abrasion
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme; Website: www.mhra.gov.uk/yellowcard.